The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1150
February 17, 2003
View Complete Issue         Table of Contents 2019 
Buprenorphine: An alternative to Methadone
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Buprenorphine: An alternative to Methadone
February 17, 2003 (Issue: 1150)
The FDA has approved the marketing of buprenorphine in sublingual tablets (Reckitt Benckiser) both alone (Subutex) and with naloxone (Suboxone) for treatment of opioid dependence. Previously available only for parenteral use in treatment of pain...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Buprenorphine: An alternative to Methadone
Article code: 1150a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.